Testing NTZ for liver cirrhosis flare-ups with risk of liver failure
Part of Digestive system clinical trials.
This study tests if adding a medication called nitazoxanide to standard care can help people with severe liver cirrhosis complications avoid progressing to acute-on-chronic liver failure. It is for adults recently hospitalized with a sudden worsening like fluid buildup (ascites), confusion from liver issues (hepatic encephalopathy), or digestive bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cirrhosis (scarring of the liver) from any cause.
- In the past 10 days, you had a sudden new problem like belly fluid buildup, confusion (hepatic encephalopathy), or bleeding from the stomach or esophagus.
- You are an adult under 75 years old.
- You can swallow pills by mouth.
- You agree to use contraception if needed, for about 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether nitazoxanide can help stop hepatic encephalopathy (a “liver-to-brain” confusion problem) from coming back. It’s for adults with cirrhosis who have had at least one past episode, aiming to improve safety and prevent recurrence.
This trial tests if a 600 mg dose of nitazoxanide (an antiparasitic drug) can help outpatients with early COVID-19 or flu recover more quickly. If you've just tested positive for COVID-19 or influenza and your symptoms started less than 48 hours ago, this study might be for you.
This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
This trial tests whether the drug N-acetylcysteine (NAC) can help people with sudden liver failure that is not caused by acetaminophen (like Tylenol). If you qualify, you may receive NAC, which might help your liver recover.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Hear when a new Acute Decompensation of Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.